Opendata, web and dolomites

MACUSTAR SIGNED

Develop and validate appropriate and acceptable outcome measures in intermediate age-related macular degeneration for future interventional clinical trials - Sofia ref.: 116076

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MACUSTAR" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAETSKLINIKUM BONN 

Organization address
address: Sigmund-Freud-Strasse 25
city: BONN
postcode: 53127
website: www.ukb.uni-bonn.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 16˙218˙917 €
 EC max contribution 8˙025˙000 € (49%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
 Code Call H2020-JTI-IMI2-2015-07-two-stage
 Funding Scheme /IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAETSKLINIKUM BONN DE (BONN) coordinator 3˙823˙388.00
2    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 1˙033˙456.00
3    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 782˙987.00
4    FONDATION DE COOPERATION SCIENTIFIQUE VOIR ET ENTENDRE FR (PARIS) participant 760˙639.00
5    MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST UK (LONDON) participant 552˙279.00
6    AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM PT (COIMBRA) participant 348˙024.00
7    CITY UNIVERSITY OF LONDON UK (LONDON) participant 280˙383.00
8    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 233˙161.00
9    THE UNIVERSITY OF SHEFFIELD UK (SHEFFIELD) participant 210˙679.00
10    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
11    CARL ZEISS MEDITEC AG DE (JENA) participant 0.00
12    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
13    NOVARTIS PHARMA AG CH (BASEL) participant 0.00

Mappa

 Project objective

Despite significant advances in the treatment and understanding of late stage age-related macular degeneration (AMD), it continues to be the main cause of irreversible severe visual loss in Europe and its prevalence and incidence will increase with current demographic trends. In order to reduce the significant burden of late stage AMD, novel interventions should aim at stopping or delaying progression from the preceding disease stage intermediate AMD (iAMD) to late stage AMD. As a prerequisite, validated clinical endpoints for iAMD are needed. These should be acceptable to regulatory agencies, health technology assessment (HTA) bodies, and payers. Currently such endpoints do not exist for iAMD clinical trials (CTs).

In addition, there is good evidence indicating that patients with iAMD experience some impairment of visual function yet it is unknown to what extend this impacts the patients’ life nor can it be reliably measured and quantified. It is also unknown whether there are specific risk factors in the population of iAMD patients which identify those with more rapid progression to late stages of the disease.

Therefore, to enable successful development of iAMD interventions validated functional, morphological and patient--reported endpoints for CTs, which are clinically meaningful and accepted by regulatory agencies, are required. In addition, functional decline in iAMD, as well as, specific risk factors for iAMD progression to late stage AMD need to be better characterized to inform and improve conduct of future iAMD CTs.

Against this background, the major objective of MACUSTAR is to develop novel clinical endpoints for CTs with a regulatory and patient access intention in patients with iAMD. Additional objectives are to characterize visual impairment in iAMD and its progression, as well as, identify risk factors for progression.

For clinical endpoint development, functional, structural and patient-reported outcome measures will be assessed with regards to

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MACUSTAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MACUSTAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.)

eHealth Week (2016)

eHealth Week 2016

Read More  

EHW15 (2015)

High Level eHealth Conference 2015

Read More  

hPSCreg (2017)

Human Puripotent Stem Cell Registry

Read More